Canaccord analyst Richard Close said he remains a buyer of Teladoc shares as recent datapoints illustrate same store growth success via client penetration. He said the company's penetration into its existing client base will allow it to generate robust organic growth. Close reiterated his Buy rating and $95 price target on Teladoc shares.

Reports Q1 revenue $646.13M, consensus $637.29M. "We are pleased to report a solid start to the year, with strength in both revenue and adjusted EBITDA in the first quarter," said Mala Murthy, acting chief executive officer and chief financial officer of Teladoc Health. "During this period of transition, our team remains laser focused on our key initiatives, which include building upon our market leadership position; driving increased product penetration through our large installed base of over 90 million virtual care members; and accelerating our bottom-line performance."